Aurinia Pharmaceuticals Inc (AUPH)

[Jesspro]

Recently published on July 2022; more exposure trickling out.
Published online: 11 Jul 2022.

“Key take away: voclosporin and belimumab improve renal response rates when added to standard-of-care therapy, with a statistically significant effect demonstrated at 24 weeks with voclosporin and 104 weeks with belimumab. An advantage of voclosporin over belimumab is that it also has a stabilizing effect on podocyte function that would be anticipated to reduce proteinuria and potentially preserve the histology of the kidney. This activity, together with the rapidity of the reduction in proteinuria, means that voclosporin would be the add-on therapy of choice in Class III–V proteinuric patients.”